Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: J Cyst Fibros. 2016 Jan 25;15(5):597–604. doi: 10.1016/j.jcf.2015.12.023

Table 2.

Pulmonary Exacerbations: Clinical Characteristics

Characteristic Total (N=73)a Mild (N=41)a Moderate/Severe
(N=32)a
Male b 16 (47) 11 (68.75) 5 (27.78)
Age at baseline (years;
median, interquartile range)
11.46 (7.53,
14.70)
8.81 (6.98,
12.94)
13.08 (10.55, 15.66)
BMI percentile at baseline
(median, interquartile range)
44 (28, 83) 51 (28.5,
75.5)
39 (24, 87)
Loss in FEV1 % predicted
from baseline (median,
interquartile range) c
7 (2, 15) 7 (1, 13) 10 (4, 17)
Severity
 Mild 41 (56.16) 41 (100.00)
 Moderate 27 (36.99) 27 (84.38)
 Severe 5 (6.85) 5 (15.62)
Symptoms
 Cough 71 (97.26) 40 (97.56) 31 (96.88)
 Fatigue 48 (65.75) 23 (56.10) 25 (78.13)
 Fever 9 (12.33) 2 (4.88) 7 (21.88)
 Weight loss 35 (47.95) 13 (31.71) 22 (68.75)
 Shortness of breath 10 (13.70) 2 (4.88) 8 (25.00)
 Crackles 29 (39.73) 8 (19.51) 21 (65.63)
 Wheeze 2 (2.74) 0 (0.00) 2 (6.25)
a

: Results represented as n(%) unless otherwise indicated.

b

: For 34 subjects (16 male, 18 female), there were 73 exacerbations; 16 subjects had only mild exacerbations and 18 subjects had at least one moderate/severe exacerbation.

c

: 70 exacerbations had information on FEV1.